Lutetium PSMA Therapy aims to improve a patients symptoms, reduce the size of of the tumour/s, and slow the growth. This therapy is used when the prostate cancer has metastasised (spread), and can be effective when alternate treatments have failed, or are causing significant harm or side-effects.
PSMA is a type of protein found on the surface of a cell in the prostate. If you have prostate cancer, your PSMA levels will a higher level than that of normal. Lutetium is a radioactive substance that damages and destroys the cancer cells in a targeted manner.
The PSMA molecule is bound with Lutetium, and travels to the unhealthy cells, meaning the rest of your body is not exposed to radiation.
Before starting this therapy, you will be referred by your Oncologist for a PET/CT scan to ensure the radiation will target the right areas during treatment.
Your doctor will explain this procedure to you carefully, and you will have time to discuss the treatment and side-effects.
Although Lutetium PSMA Therapy can reduce the size of of the tumours and slow the growth, it does not act to cure the cancer.
For more information please visit GenesisCare Theranostics, email at theranosticsreception@genesiscare.com.au or phone at 08 9438 8500 to learn more about advanced cancer therapies.